Physician profile
Kathy Sam
NPI 1427203819
$23,122.10
in general payments reported to CMS, 2019-2025
87 companies · $3,739 in 2025
The $3,739 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,890 · 2020: $1,612 · 2021: $2,885 · 2022: $3,863 · 2023: $3,985 · 2024: $4,148 · 2025: $3,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Grant: $235 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,610.94 |
| Grant | $235.20 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,670.54 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $1,664.69 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $1,660.93 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $1,366.42 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $1,294.43 | 2019-2025 | |
| Janssen Biotech, INC. | $1,261.61 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Glaxosmithkline, LLC. | $776.25 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $749.50 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $660.91 | 2019-2025 | |
| Abbvie INC. | $622.96 | 2022-2025 | Venclexta |
| Rigel Pharmaceuticals, INC. | $588.91 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Amgen INC. | $561.88 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Incyte Corporation | $517.38 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Genentech USA, INC. | $492.82 | 2019-2025 | Tecentriq, Polivy, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $471.70 | 2019-2023 | Imbruvica, Epkinly |
Show all 87 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $452.29 | 2019-2025 | |
| Eisai INC. | $442.93 | 2019-2025 | |
| Beigene USA, INC. | $390.38 | 2022-2024 | Brukinsa |
| Seagen INC. | $372.90 | 2019-2023 | Adcetris |
| Puma Biotechnology, INC. | $332.13 | 2019-2025 | Nerlynx |
| Takeda Pharmaceuticals U.S.A., INC. | $326.54 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Array Biopharma INC | $317.77 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Gilead Sciences, INC. | $306.05 | 2019-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $304.05 | 2022-2025 | |
| Daiichi Sankyo INC. | $299.83 | 2020-2025 | Enhertu, Datroway |
| Myriad Genetic Laboratories, INC. | $262.02 | 2023-2024 | Myrisk, Precisetumor |
| Exelixis INC. | $234.71 | 2020-2025 | Cabometyx |
| Taiho Oncology, INC. | $224.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.74 | 2019-2023 | Gilotrif |
| Stemline Therapeutics INC. | $214.92 | 2023-2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $208.62 | 2019-2024 | Libtayo |
| Kite Pharma, INC. | $196.57 | 2020-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $195.58 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Astellas Pharma US INC | $192.39 | 2019-2025 | Xtandi, Padcev, Xospata |
| Janssen Pharmaceuticals, INC | $191.17 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $184.51 | 2021-2024 | Clonoseq |
| Tersera Therapeutics LLC | $175.79 | 2019-2024 | Zoladex |
| Agios Pharmaceuticals, INC. | $141.29 | 2019-2022 | |
| Pharmaessentia USA Corporation | $138.07 | 2022-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $131.73 | 2019-2024 | |
| Morphosys, US INC. | $127.07 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $126.03 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $121.50 | 2019-2024 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $110.27 | 2019-2025 | Onivyde |
| Springworks Therapeutics, INC. | $109.67 | 2024-2025 | Ogsiveo, Gomekli |
| Tesaro, INC. | $98.46 | 2019 | |
| Beone Medicines USA, INC. | $85.32 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $84.34 | 2022-2024 | Fotivda |
| Geron Corporation | $81.71 | 2025 | Rytelo |
| Emd Serono, INC. | $79.83 | 2019-2025 | |
| Mirati Therapeutics, INC. | $75.15 | 2023-2024 | Krazati |
| Teva Pharmaceuticals USA, INC. | $72.93 | 2019-2020 | |
| Sobi, INC | $70.76 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $61.49 | 2019-2020 | |
| Verastem, INC. | $60.08 | 2019 | |
| Immunogen, INC. | $51.79 | 2023 | Elahere |
| Syndax Pharmaceuticals, INC. | $50.19 | 2025 | |
| Boston Scientific Corporation | $49.07 | 2022-2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Apellis Pharmaceuticals, INC. | $47.76 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $46.57 | 2023-2025 | Orgovyx |
| Cti Biopharma Corp. | $44.91 | 2023 | Vonjo |
| Mylan Institutional INC. | $44.89 | 2019 | |
| Karyopharm Therapeutics INC. | $37.84 | 2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $36.86 | 2020-2025 | Monoferric |
| Secura Bio, INC. | $36.06 | 2021-2024 | Copiktra |
| Iovance Biotherapeutics, INC. | $32.89 | 2024 | Amtagvi |
| Fortovia Therapeutics, INC. | $31.91 | 2019 | |
| Dendreon Pharmaceuticals LLC | $31.55 | 2024 | Provenge |
| Dova Pharmaceuticals | $31.11 | 2019-2020 | |
| Spectrum Pharmaceuticals INC. | $29.01 | 2025 | Rolvedon |
| Amneal Pharmaceuticals LLC | $27.11 | 2025 | Alymsys |
| Foundation Medicine, INC. | $26.28 | 2019 | |
| Acceleron Pharma, INC. | $24.86 | 2020 | |
| Immunomedics, INC. | $24.52 | 2020 | |
| Biocon Biologics INC | $24.24 | 2024 | Ogivri |
| Clovis Oncology, INC. | $23.41 | 2019 | |
| Kyowa Kirin, INC. | $23.10 | 2019-2020 | |
| Erbe USA INC | $22.00 | 2025 | Erbecryo2 |
| Sirtex Medical INC | $18.93 | 2023 | Sir-Spheres Microspheres |
| Advanced Accelerator Applications | $18.62 | 2019 | |
| Eusa Pharma (US) LLC | $18.32 | 2020 | |
| Tempus Ai, INC | $16.87 | 2024 | |
| Cycle Pharmaceuticals INC | $16.77 | 2025 | Phyrago |
| Verity Pharmaceuticals INC. | $15.61 | 2022 | |
| Stimwave Technologies Incorporated | $14.59 | 2019 | |
| Acrotech Biopharma INC. | $13.77 | 2024 | Beleodaq |
| Amag Pharmaceuticals, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
Keytruda $716Verzenio $399Opdualag $381Jaypirca $362Enhertu $350Brukinsa $321Opdivo $315Reblozyl $312Elahere $305Pomalyst $303Calquence $274Tavalisse $268Rezlidhia $268Venclexta $258Imfinzi $246Xtandi $243Kisqali $240Lenvima $237Lynparza $237Retevmo $228Imbruvica $227Orserdu $215Rybrevant $211Talzenna $198Darzalex $186Cabometyx $184Ojjaara $178Ibrance $172Orgovyx $171Jakafi $162Tukysa $162Myrisk $156Zepzelca $156Erleada $149Jemperli $146Epkinly $141Tecentriq $135Promacta $133Yescarta $133Qinlock $127Tecvayli $126Fabhalta $123Clonoseq $119Vonjo $116Adcetris $112Zejula $110Padcev $106Precisetumor $106Braftovi $104Mektovi $104Trodelvy $100Nerlynx $97.70Polivy $95.37Besremi $93.58Sarclisa $87.28Libtayo $86.77Rytelo $81.71Ogsiveo $80.21Talvey $79.34Krazati $75.15Inqovi $74.87Lonsurf $74.87Inlyta $73.32Monjuvi $71.47Niktimvo $68.40Fotivda $62.54Fruzaqla $62.35Ultomiris $60.70Gavreto $59.86Romvimza $56.98Lumakras $56.43Welireg $53.26Kyprolis $52.34Itovebi $49.56Shingrix $48.38Lorbrena $48.00Ninlaro $47.56Onivyde $46.02Paxlovid $40.27Xpovio $37.84Lunsumio $36.44Xospata $35.45Amtagvi $32.89Enjaymo $32.66Tgct $32.43Provenge $31.55Datroway $29.86Gomekli $29.46Tevimbra $29.23Rolvedon $29.01Emrelis $27.19Alymsys $27.11Stivarga $25.54Zoladex $25.36Therasphere Y90 Glass Microspheres 10 Gbq $25.15Bosulif $24.44Elrexfio $24.44Besponsa $24.44Ogivri $24.24Scemblix $24.24
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.